Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E (Alpha/Beta/Delta/Omicron Variants S-Trimer COVID-19 Vaccine) in Population Aged ≥18 Years

NCT05308576 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT05308576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05308576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E (Alpha/Beta/Delta/Omicron Variants S-Trimer COVID-19 Vaccine) in Population Aged ≥18 Years
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
December 26, 2022
Completion date
April 30, 2024
Enrollment
10,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection